Edition:
United States

Neogenomics Inc (NEO.OQ)

NEO.OQ on NASDAQ Stock Exchange Capital Market

9.18USD
15 Dec 2017
Change (% chg)

$0.12 (+1.32%)
Prev Close
$9.06
Open
$9.05
Day's High
$9.34
Day's Low
$9.01
Volume
364,934
Avg. Vol
112,651
52-wk High
$11.55
52-wk Low
$7.14

Latest Key Developments (Source: Significant Developments)

NeoGenomics reports Q3 adj earnings per share of $0.01
Wednesday, 25 Oct 2017 07:00am EDT 

Oct 25 (Reuters) - Neogenomics Inc :NeoGenomics reports revenue of $63.1 million on 17 percent volume growth and 11 percent reduction in average cost per test in the third quarter of 2017.Q3 adjusted earnings per share $0.01.Q3 revenue $63.1 million versus I/B/E/S view $63.5 million.Q3 earnings per share view $0.02 -- Thomson Reuters I/B/E/S.Sees Q4 loss per share $0.03 to $0.04.Sees Q4 revenue $65 million to $67 million.Q3 GAAP loss per share $0.10.Q4 earnings per share view $0.04, revenue view $66.8 million -- Thomson Reuters I/B/E/S.NeoGenomics Inc - expects ‍Q4 adjusted diluted EPS to be $0.04 - $0.05 per share​.  Full Article

NeoGenomics sees Q3 revenue of about $63.1 mln
Thursday, 12 Oct 2017 04:01pm EDT 

Oct 12 (Reuters) - NeoGenomics Inc :NeoGenomics announces preliminary quarter 3 results, financial impacts of hurricanes and summary quarter 4 guidance.NeoGenomics Inc - ‍it expects to report quarter 3 revenue of approximately $63.1 million and adjusted EBITDA of approximately $6.0 million​.NeoGenomics Inc - ‍NeoGenomics estimates that hurricanes Harvey and Irma depressed revenue by approximately $1.0 million in quarter 3​.NeoGenomics inc - ‍in addition, as a result of divestiture of pathlogic, Q3 revenue will be approximately $1.3 million less than in quarter 2​.NeoGenomics Inc - ‍expects consolidated revenue of $65 million - $67 million and adjusted EBITDA of $9 million -10 million in Q4​.NeoGenomics-For Q3,expects to record $1.3 million revenue adjustment to reflect change in process for estimating revenue for unbilled tests at quarter-end​.Q3 revenue view $65.9 million -- Thomson Reuters I/B/E/S.Q4 revenue view $69.1 million -- Thomson Reuters I/B/E/S.  Full Article

Neogenomics reports on impact from hurricane Irma
Monday, 11 Sep 2017 03:04pm EDT 

Sept 11 (Reuters) - Neogenomics Inc ::Neogenomics reports on impacts from hurricane Irma.Hurricane Irma had minimal impacts to Fort Myers, FL facility​.Expect to resume normal operations in Fort Myers facility by Wednesday of this week.  Full Article

Neogenomics Inc Q2 revenue $66.1 million
Tuesday, 25 Jul 2017 07:00am EDT 

July 25 (Reuters) - Neogenomics Inc :Neogenomics reports record revenue of $66.1 million on 16% volume growth and 13% reduction in average cost per test in the second quarter of 2017.Q2 adjusted earnings per share $0.04.Q2 revenue $66.1 million versus I/B/E/S view $63 million.Q2 earnings per share view $0.03 -- Thomson Reuters I/B/E/S.Q2 GAAP loss per share $0.03.Neogenomics Inc says reiterated guidance for fiscal year 2017.FY2017 earnings per share view $0.18, revenue view $258.2 million -- Thomson Reuters I/B/E/S.  Full Article

Neogenomics announces expansion of its immuno-oncology profiling test menu
Friday, 2 Jun 2017 07:00am EDT 

June 2 (Reuters) - Neogenomics Inc :Announced an expansion of its immuno-oncology profiling test menu.Company has expanded its neotype cancer profiles to include tumor mutation burden and microsatellite instability testing.  Full Article

NeoGenomics sees Q2 2017 adjusted earnings per share $0.03-$0.04
Wednesday, 26 Apr 2017 07:00am EDT 

April 26 (Reuters) - NeoGenomics Inc :Neogenomics reports 15% volume growth and 10% reduction in average cost per test in the first quarter of 2017.Q1 adjusted earnings per share $0.03.Sees q2 2017 adjusted earnings per share $0.03 to $0.04.Sees q2 2017 loss per share $0.03 to $0.04.Sees q2 2017 revenue $62 million to $64 million.Q1 revenue $61.7 million versus i/b/e/s view $61.6 million.Q1 gaap loss per share $0.04.Q1 earnings per share view $0.03 -- Thomson Reuters I/B/E/S.Neogenomics inc sees full year consolidated 2017 revenue to be $255 - $265 million.Neogenomics inc sees 2017 gaap diluted eps to be a loss of $0.10 - loss of $0.06 per share.Neogenomics inc - expects adjusted ebitda to be $39 - $46 million for 2017.Neogenomics inc sees adjusted diluted eps to be $0.17 - $0.21 per share for 2017.Fy2017 earnings per share view $0.19, revenue view $264.6 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $0.04, revenue view $66.0 million -- Thomson Reuters I/B/E/S.  Full Article

NeoGenomics and Definiens to develop novel assays for clinical trials & clinical testing
Monday, 13 Mar 2017 07:00am EDT 

NeoGenomics Inc - : NeoGenomics and Definiens enter into agreement to develop novel assays for clinical trials & clinical testing . Co, definiens expanded alliance to develop and automate analysis of new biomarker assays for clinical trials, routine clinical testing .definiens to provide automated quantitative biomarker solutions to support neogenomics' immunohistochemistry services.  Full Article

NeoGenomics Q4 GAAP loss per share $0.18
Wednesday, 22 Feb 2017 07:00am EST 

NeoGenomics Inc : NeoGenomics reports 122% revenue growth to $60.5 million and 11% reduction in average cost per test in the fourth quarter of 2016 . Q4 adjusted earnings per share $0.05 . Q4 GAAP loss per share $0.18 . Q4 revenue $60.5 million versus I/B/E/S view $61.8 million . Q4 earnings per share view $0.03 -- Thomson Reuters I/B/E/S . NeoGenomics Inc - company expects full year consolidated 2017 revenue to be in range of $260 - $275 million . NeoGenomics Inc -sees FY adjusted EBITDA to be in range of $42 - $50 million . NeoGenomics Inc - sees FY adjusted diluted EPS to be in range of $0.17 - $0.22 per share .NeoGenomics Inc - sees FY GAAP diluted EPS to be a loss of ($0.10) - ($0.05) per share.  Full Article

Neogenomics Inc, some units and Neogenomics Laboratories enter credit agreement - SEC filing
Tuesday, 27 Dec 2016 05:44pm EST 

Neogenomics Inc : Neogenomics Inc - on December 22, 2016, Neogenomics Laboratories Inc and co and units entered into a credit agreement - SEC filing . Neogenomics Inc - credit agreement provides incremental facility capacity of $50 million - SEC filing . Neogenomics Inc says credit agreement provides for a $75 million revolving credit facility and a $75 million term loan facility .Neogenomics Inc - any principal outstanding under revolving credit facility is due and payable on December 21, 2021.  Full Article

NeoGenomics sees FY 2016 GAAP loss of $0.30-$0.28/share
Thursday, 22 Dec 2016 09:51am EST 

NeoGenomics Inc : NeoGenomics also revised its guidance for fiscal year 2016 . Sees FY 2016 revenue $244 mln to $246 mln . For FY 2016 company now expects GAAP diluted EPS to be a loss of $0.30 - $0.28 per share . FY 2016 earnings per share view $0.14, revenue view $247.6 mln -- Thomson Reuters I/B/E/S . FY 2016 adjusted diluted EPS to be approximately $0.13 - $0.15 per share . Expect only minimal increases in 2017 interest expense despite higher principal outstanding . Have $52 mln available under revolving credit facility to pursue strategic opportunities . NeoGenomics closes $150 mln senior credit facility .Facility also reduces our weighted average cost of senior debt capital to roughly half previous level.  Full Article

BRIEF-Neogenomics Inc files for non-timely 10-Q - SEC filing ‍​

* Neogenomics Inc files for non-timely 10-Q - SEC filing ‍​ Source text: (http://bit.ly/2AozWFk) Further company coverage: